OliX Pharmaceuticals Raises KRW 110 Billion From L’Oréal Venture Fund BOLD And Weiss Asset
SWI Editorial Staff2026-06-04T07:37:23-07:00OliX Pharmaceuticals, a South Korea-based biotechnology company focused on RNA interference (RNAi) therapeutics, announced that it has secured approximately KRW 110 billion (about $81 million) through a third-party allotment ...









